The Neoadjuvant Therapy for Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 2105
Special Issue Editors
Interests: ovarian cancer; breast cancer; novel therapy; immune therapy; CTCs; breast cancer immunitherapy
Special Issue Information
Dear Colleagues,
Neoadjuvant chemotherapy in breast cancer has emerged as a significant paradigm in redefining the approach to treatment planning and patient outcomes. This innovative therapeutic strategy involves administering chemotherapy before surgical intervention, a departure from its conventional post-surgery counterpart. Neoadjuvant chemotherapy offers several advantages, including the potential for tumor size reduction, facilitating less invasive surgical procedures, and providing an in vivo assessment of the tumor's response to treatment. This approach not only improves the chances of achieving complete pathological response but also enables the tailoring of subsequent treatment strategies based on the tumor's biological behavior during treatment. This Special Issue delves into the rationale, benefits, challenges, and recent advancements surrounding neoadjuvant chemotherapy in breast cancer, highlighting its transformative role in optimizing patient care and enhancing the overall management of this prevalent malignancy. We invite all interested authors to contribute their work concerning breast cancer, neoadjuvant treatment, outcome studies, and molecular treatments.
We look forward to receiving your contributions.
Dr. Marcus Vetter
Dr. Cvetka Grašič-Kuhar
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- neoadjuvant treatment
- innovative therapy
- outcome studies
- molecular treatments
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
